Enzymestructur of Aurase designed for BRAIN Annual Report Cover 2018-19
Annual Report 2018/19

Pioneering Bioproducts

Industrial biotechnology enables natural raw materials to be utilized efficiently, industrial manufacturing processes to be improved and new biobased products to be created. With its wide range of biobased ingredients and processes, the BRAIN Group makes a significant contribution to making consumer goods more effective and healthier and to making industrial processes more efficient and more sustainable. The company is an active pioneer in the move away from fossil raw materials and towards sustainably produced and utilized biological resources.

Financial Publication
Cover GB 2018-19

Annual Report 2018/19

(full document)

Download PDF
38.6
Revenue
(in € million)
Previous year: 27, 1
–2.1
Adjusted EBITDA
(in € million)
Previous year: –5.3
25.8 %
Equity ratio (in %)
(in € million)
Previous year: 38.2 %
–3.4
Cash flows from operating activities
(in € million)
Previous year: –5.4

“Underpinned by the certainty that BRAIN’s continued growth can be achieved primarily through product scalable businesses, from the beginning of 2018 we implemented measures to strengthen this segment.”

Dr. Jürgen Eck
Member of the founding team and CEO (until 31.12.2019) of BRAIN AG
Portrait of Jürgen Eck, BRAIN AG
BRAIN Management Board 2019

Management Board interview

Dr. Jürgen Eck has been co-founder and CEO* of BRAIN AG since July 2015. Ludger Roedder took over the newly created position of Chief Business Officer (CBO) on 1 January 2019. Manfred Bender has been Chief Financial Officer (CFO) since 1 January 2019. Read the Interview here.

To the interview

*until 31.12.2019

Adriaan (Aryan) Moelker BRAIN

BRAIN sets course for the future

Dr. Jürgen Eck, co-founder of BRAIN, long-standing CTO and CEO since 1 August 2015, will hand over his mandate as CEO to Adriaan Moelker, who is to head the Group from 1 February 2020. Mr. Moelker will in future be responsible for the enhanced commercialization of the product and project businesses with the aim of leading the company into its next expansion phase.

To the article

Bioeconomy – the biological transformation of industry

In order to meet rising demand for sustainably produced or biobased goods, both policymakers and business are driving the biologization of industrial processes, goods and consumer goods. New technologies, processes, services and business models are helping to make the production and consumption cycle more sustainable, thereby establishing the basis for a forward-looking economy and way of life.

To the article bioeconomy

Business options

The company prioritizes the marketing of product-scalable business options in order to implement its growth strategy. These are based on the BRAIN Group’s product offering to industrial customers (B2B business) as well as on products developed together with industrial partners and subsequent license-based marketing.

Tailor-made solutions developed on the basis of R&D performance payments in the context of R&D partnerships comprise a further business option.

A third business option is to develop our own product candidates. Discoveries and insights from these two areas are combined within the new product development pipeline in order to generate our own innovative project ideas. The in-house development of such ideas to market-launch stage lays the foundation for the company’s future organic growth.

Some examples from the three business options can be found in the booklets of the annual report:

Healthier and more efficient consumer products

From foods through to care products, consumers are increasingly selecting products based on natural ingredients. This has led manufacturers to adopt new approaches when utilizing natural basic materials and biotechnology production processes. BRAIN is deploying its specialty enzymes, in particular, in order to respond to the requirements of the high-growth markets for biobased products and processes. These specialty enzymes generate distinctive aromas, accelerate biochemical conversion processes and extract every last bit of goodness from fruit used to produce juices, oils and wine.

Download the Booklet B2B product portfolio

Real innovations for highly profitable markets

BRAIN is continuously expanding its development pipeline, adding new validated product ideas and harnessing business potential in promising areas. Innovations are generated based on novel cell models for simulating sensorial reactions, as well as from unique methods for decoding how microorganisms work. Examples of applications for new product ideas range from natural sweeteners to the sustainable extraction of metal.

Download the Booklet New product development

From biotechnology to commercial success

BRAIN combines a first-class technology portfolio with a unique proprietary BioArchive. Both the company’s own business units and partners from industry benefit from this powerful combination of inhouse resources and the application of cutting-edge, high-tech methodology.

Download the Booklet Tailor-made solutions

Investor Relations service

You want to invest in BRAIN or have questions? We are here for you. Please get in touch with us.

Investor Relations Contact

Share this page